Target intelligence / Profile preview

Pathogenic bacteria (Staphylococcus spp., Shigella spp., EPEC, Salmonella spp.)

Molecular classification
Other (Bacterial Pathogens)
01

Overview

This entry represents a collection of pathogenic bacteria including Gram-positive Staphylococcus species and Gram-negative enteric pathogens like Shigella, enteropathogenic Escherichia coli (EPEC), and Salmonella. Staphylococcus spp. are major causes of skin, soft tissue, and systemic infections, often characterized by their ability to produce potent exotoxins and form biofilms (StatPearls, 2023). Shigella flexneri and Shigella sonnei are highly infectious agents of bacillary dysentery, primarily targeting the human colon through intracellular invasion (CDC, 2023). Enteropathogenic Escherichia coli (EPEC) is a leading cause of persistent diarrhea in infants, utilizing a type III secretion system to induce attaching and effacing lesions on the intestinal mucosa (NIH, 2013). Salmonella typhimurium and Salmonella enteritidis are key serovars responsible for non-typhoidal salmonellosis, typically manifesting as acute gastroenteritis following the ingestion of contaminated food (WHO, 2023). These pathogens are collectively targeted by various classes of antibiotics, though the emergence of multi-drug resistance remains a critical therapeutic challenge. Because this entry lists multiple distinct species and genera rather than a specific molecular target, it is classified as a pathogen group rather than a single therapeutic target.

Other names
Staphylococcus spp.Shigella flexneriShigella sonneiEnteropathogenic Escherichia coliSalmonella typhimuriumSalmonella enteritidisEnteric pathogensFoodborne bacteria
02

Mechanism of action

Antibiotics targeting these pathogens typically act through the inhibition of cell wall synthesis (e.g., beta-lactams), protein synthesis (e.g., macrolides), or DNA replication and repair (e.g., fluoroquinolones).

03

Biological functions

Bacterial pathogenesisToxin productionCellular invasionBiofilm formationOther
04

Disease associations

InfectionGastroenteritisSepsisFood poisoningShigellosisSalmonellosisOther
05

Safety considerations

Antimicrobial resistance (AMR)Disruption of commensal microbiotaRisk of Clostridioides difficile overgrowthJarisch-Herxheimer reaction
06

Interacting drugs

Ciprofloxacin

5 more in the full profile.

07

Biomarkers

Bacterial culturePolymerase chain reaction (PCR)Enzyme-linked immunosorbent assay (ELISA)Antibiogram

Beyond the preview

Go deeper on Pathogenic bacteria (Staphylococcus spp., Shigella spp., EPEC, Salmonella spp.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic bacteria (Staphylococcus spp., Shigella spp., EPEC, Salmonella spp.).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call